MYSTIC MYC suppression through innovative chemistry
- Coordinator
- Universiteit Leiden, Netherlands
- Runs
- 1 May 2025 to 31 October 2026
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101213005
What the project is doing
In the project's own words, from its summary on CORDIS.
MYSTIC aims to revolutionize cancer treatment by advancing HeloMYC, a novel cell-penetrating protein therapeutic that targets the oncogenic transcription factor MYC. Developed using our innovative reCHEMbinant platform, HeloMYC represents a breakthrough in addressing an ""undruggable"" intracellular target, combining the specificity of protein therapeutics with enhanced cell penetration and stability. MYC, implicated in over 50% of human cancers, has long been considered an elusive target due to its complex protein-protein and protein-nucleic acid interactions and lack of druggable pockets.
HeloMYC is a protein based MYC inhibitor that overcomes these challenges and through strategic chemical modifications achieves potent intracellular activity against MYC-driven transcription in cancer cells in preliminary studies. This 18 months project will focus on three key objectives: advancing HeloMYC's preclinical development
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Leiden | Leiden | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI